- Home
- ZNTL vs PFO Comparison
ZNTL vs PFO Comparison
Compare ZNTL & PFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZNTL | PFO |
|---|---|---|
| Founded | 2014 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.3M | 125.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZNTL | PFO |
|---|---|---|
| Price | $1.43 | $9.43 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $5.87 | N/A |
| AVG Volume (30 Days) | ★ 495.7K | 31.8K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $26,865,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.01 | $6.90 |
| 52 Week High | $3.72 | $8.51 |
Technical Indicators
Market Signals| Indicator | ZNTL | PFO |
|---|---|---|
| Relative Strength Index (RSI) | 52.35 | 46.45 |
| Support Level | $1.34 | $9.35 |
| Resistance Level | $1.45 | $9.51 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 70.59 | 56.43 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.